Michael Barbella, Managing Editor06.07.23
There's a lucrative future in orthobiologics.
Coherent Market Insights estimates the global orthobiologics market 2022 value to be $6.51 billion and forecasts it to expand 5.9% annually through 2030 to top $10.3 billion. The major growth driver is anticipated to be the adoption of inorganic strategies such as product launches by key market players. For instance, in March 2022, Molecular Matrix Inc. debuted Osteo-P, a synthetic bone graft substitute made by using a hyper-crosslinked carbohydrate polymer (HCCP) technology platform that optimizes the microenvironment for bone repair and regeneration.
Last June, Isto Biologics launched Influx Fibrant, a new line of advanced allograft, an unprecedented line of functional constructs derived from cortical allograft.
Among product type, bone allograft is expected to hold a dominant market position due to increasing product approvals by regulatory authorities such as the U.S. Food and Drug Administration (FDA). In July 2020, Baxter received FDA approval for altapore-shaped bioactive bone graft, which is is designed to enhance bone growth and help to achieve fusion, thereby reducing pain.
Key market players include Zimmer Biomet Holdings Inc., Bone Biologics Corp., Globus Medical, Smith+Nephew plc, Stryker Corp., ATEC Spine Inc., XTANT MEDICAL, Johnson & Johnson Services Inc., Exactech Inc., Integra LifeSciences, Medtronic, NuVasive, Inc., Orthofix LLC, SeaSpine, ChitogenX Inc., Spine Wave Inc., Molecular Matrix Inc., Isto Biologics, Baxter, Locate Bio Limited, Cerapedics, Ossifix Orthopedics, and Aziyo.
Coherent Market Insights estimates the global orthobiologics market 2022 value to be $6.51 billion and forecasts it to expand 5.9% annually through 2030 to top $10.3 billion. The major growth driver is anticipated to be the adoption of inorganic strategies such as product launches by key market players. For instance, in March 2022, Molecular Matrix Inc. debuted Osteo-P, a synthetic bone graft substitute made by using a hyper-crosslinked carbohydrate polymer (HCCP) technology platform that optimizes the microenvironment for bone repair and regeneration.
Last June, Isto Biologics launched Influx Fibrant, a new line of advanced allograft, an unprecedented line of functional constructs derived from cortical allograft.
Among product type, bone allograft is expected to hold a dominant market position due to increasing product approvals by regulatory authorities such as the U.S. Food and Drug Administration (FDA). In July 2020, Baxter received FDA approval for altapore-shaped bioactive bone graft, which is is designed to enhance bone growth and help to achieve fusion, thereby reducing pain.
Key market players include Zimmer Biomet Holdings Inc., Bone Biologics Corp., Globus Medical, Smith+Nephew plc, Stryker Corp., ATEC Spine Inc., XTANT MEDICAL, Johnson & Johnson Services Inc., Exactech Inc., Integra LifeSciences, Medtronic, NuVasive, Inc., Orthofix LLC, SeaSpine, ChitogenX Inc., Spine Wave Inc., Molecular Matrix Inc., Isto Biologics, Baxter, Locate Bio Limited, Cerapedics, Ossifix Orthopedics, and Aziyo.